Next Phase Newsletter

A private investment firm based in California invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seat, but prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2009 and is based in Paris, France. The firm currently manages three Biofunds, the newest of which closed in 2020 and focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2002 and has offices in San Francisco, CA, and Boston, MA. The firm is investing from its sixth fund, which closed at $350 million in 2018. The firm invests in seed and Series A rounds and has a strong preference for being the first institutional investor in a company. The firm typically reserves a total of $25 million to invest over the life of a portfolio company. The firm invests in the USA and Canada, and typically makes about 5 allocations per year.

The firm is primarily focused on therapeutics, and generally will no longer invest in technologies with a medical device regulatory pathway. The firm prefers to invest in platform technologies that have attained significant preclinical proof of concept data, preferably with published data and evidence that shows reproduction of theory. The firm prefers that platform technologies have potential to bring therapeutics to market in the short-term. The firm will consider therapeutic opportunities in any indication space and is agnostic to modality (i.e. small molecule, large molecule, cell/gene therapy). Additionally, the firm invests in biotech research tools, such as sequencing technologies and discovery platforms.

The firm prefers to work with strong scientific teams. The firm invests only in the USA and Canada and does not consider international opportunities unless the company has a significant US presence. The firm generally does not invest in companies that have previously received investments from an institutional investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The fund is a $350M specialist venture capital fund based in Boston, MA and London, UK. The fund was founded in 2015 with the vision of delivering high-impact therapeutics for age-related dementia. The fund is looking to invest in therapeutics to treat all forms of dementia, including Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s Disease (HD). The fund will invest in all stages, but prefers to invest in companies with novel therapeutics, and supports the companies through multiple rounds to an exit, investing $15-25M over the life of a company. The fund is willing to invest globally.

The fund is open to all forms of therapeutics and has a focus on five scientific themes: neuroinflammation, proteostasis, synaptic physiology, genomic instability, and platform technologies. However, the fund is always open to new scientific approaches for treatments and is willing to consider all mechanisms of action.

The fund is open to leading, or following, and takes a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A biotech early stage investment firm headquartered in Asia invests from an evergreen fund backed by a family office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Western Europe makes equity investments in early-to-late stage therapeutics, diagnostics, and medical devices companies. The firm can generally allocate between €2M to €10M. The firm only invests in companies that are based in Central and Western Europe. The firm is actively seeking new investment opportunities.

The firm is very opportunistic in the life sciences space. The firm focuses on therapeutics, diagnostics, and medical devices companies and is also interested in digital health. The firm targets therapeutic products in clinical trials or which are ready to enter Phase I, and medical devices which are CE Mark ready.  The firm is very opportunistic in terms of subsectors and indications. However, the firm does not invest in cosmetics and dental devices.  The firm strongly prefers companies developing products that address a highly unmet medical need. In digital health, the firm prefers to invest in products that have or are pursuing regulatory approval to monitor or treat a condition in which there is an unmet medical need. Generally these products will include both a hardware and a software component.  The firm is not interested in consumer or lifestyle health products.  The firm invested in companies that are developing small molecule therapeutics for women’s health and diagnostics targeting autoimmune, allergic, eye, inflammatory, liver diseases, and also in company developing device to treat prostate cancer.

The firm plays the role of lead or co-lead investor in the large majority of its financing rounds. The firm requires a board seat in its portfolio companies. The firm seeks a company with a strong and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.